PedAM
Pediatric Disease Annotations & Medicines
| leydig cell tumor | ||||
| Disease ID | 1362 |
|---|---|
| Disease | leydig cell tumor |
| Definition | Gonadal interstitial or stromal cell neoplasm composed of only LEYDIG CELLS. These tumors may produce one or more of the steroid hormones such as ANDROGENS; ESTROGENS; and CORTICOSTEROIDS. Clinical symptoms include testicular swelling, GYNECOMASTIA, sexual precocity in children, or virilization (VIRILISM) in females. |
| Synonym | [m]leydig cell tumor nos [m]leydig cell tumor nos (morphologic abnormality) [m]leydig cell tumour nos cell leydig tumors cell leydig tumour cells leydig tumor interstitial cell neoplasm interstitial cell tumor interstitial cell tumor, nos interstitial cell tumors interstitial cell tumour leydig cell neoplasm leydig cell tumor (morphologic abnormality) leydig cell tumor [disease/finding] leydig cell tumor, no icd-o subtype leydig cell tumor, no icd-o subtype (morphologic abnormality) leydig cell tumor, no international classification of diseases for oncology subtype leydig cell tumor, no international classification of diseases for oncology subtype (morphologic abnormality) leydig cell tumor, nos leydig cell tumour leydig cell tumour, no icd-o subtype testis, interstitial cell tumor tumor, interstitial cell tumor, leydig cell tumors, interstitial cell |
| DOID | |
| UMLS | C0023601 |
| MeSH | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:12) C0001627 | congenital adrenal hyperplasia | 2 C1621895 | adrenal hyperplasia | 2 C0022735 | klinefelter syndrome | 1 C0018023 | nodular goiter | 1 C0153676 | lung metastasis | 1 C0007130 | mucinous adenocarcinoma | 1 C0154209 | hyperestrogenism | 1 C0039585 | androgen insensitivity syndrome | 1 C0034013 | precocious puberty | 1 C0001418 | adenocarcinoma | 1 C0342208 | multinodular goiter | 1 C0034013 | true precocious puberty | 1 |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:3) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | Entrez_id | Symbol | Score | Resource(Total Genes:46) 64132 | XYLT2 | DISEASES 2099 | ESR1 | DISEASES 5008 | OSM | DISEASES 4254 | KITLG | DISEASES 2693 | GHSR | DISEASES 1588 | CYP19A1 | DISEASES 949 | SCARB1 | DISEASES 6855 | SYP | DISEASES 5443 | POMC | DISEASES 1583 | CYP11A1 | DISEASES 84432 | PROK1 | DISEASES 6770 | STAR | DISEASES 23082 | PPRC1 | DISEASES 5741 | PTH | DISEASES 3815 | KIT | DISEASES 1584 | CYP11B1 | DISEASES 143689 | PIWIL4 | DISEASES 1241 | LTB4R | DISEASES 794 | CALB2 | DISEASES 653499 | LGALS7B | DISEASES 1442 | CSH1 | DISEASES 8630 | HSD17B6 | DISEASES 3640 | INSL3 | DISEASES 23212 | RRS1 | DISEASES 1555 | CYP2B6 | DISEASES 7490 | WT1 | DISEASES 2626 | GATA4 | DISEASES 2100 | ESR2 | DISEASES 7316 | UBC | DISEASES 10298 | PAK4 | DISEASES 2494 | NR5A2 | DISEASES 3283 | HSD3B1 | DISEASES 1586 | CYP17A1 | DISEASES 2778 | GNAS | DISEASES 2516 | NR5A1 | DISEASES 240 | ALOX5 | DISEASES 367 | AR | DISEASES 3963 | LGALS7 | DISEASES 2315 | MLANA | DISEASES 6736 | SRY | DISEASES 1443 | CSH2 | DISEASES 174 | AFP | DISEASES 5744 | PTHLH | DISEASES 1589 | CYP21A2 | DISEASES 196527 | ANO6 | DISEASES 3451 | IFNA17 | DISEASES |
| Locus | (Waiting for update.) |
| Disease ID | 1362 |
|---|---|
| Disease | leydig cell tumor |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:6) |
| Disease ID | 1362 |
|---|---|
| Disease | leydig cell tumor |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs121912532 | 20873084 | 3973 | LHCGR | umls:C0023601 | BeFree | A left orchiectomy was performed, and histopathology revealed a well-circumscribed Leydig cell tumor Molecular study of the exon 11 of the LHR gene revealed a missense mutation at the nucleotide position 1,732, leading to a substitution of histidine for aspartic acid at codon 578. | 0.120271442 | 2010 | LHCGR;STON1-GTF2A1L | 2 | 48688065 | C | T,G,A |
| rs2959656 | 24997771 | 4221 | MEN1 | umls:C0023601 | BeFree | The biological impact of the p.Ala541Thr variant on cell growth was additionally investigated on menin-deficient Leydig cell tumour (LCT)10 cells generated from Men1+/Men1- heterozygous knock-out mice, and compared with wild type (WT). | 0.000271442 | 2014 | MEN1;MAP4K2 | 11 | 64804546 | T | C |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0023601 | indomethacin | D007213 | 53-86-1 | leydig cell tumor | MESH:D007984 | marker/mechanism | 1477515 | ||
| C0023601 | lansoprazole | D064747 | - | leydig cell tumor | MESH:D007984 | marker/mechanism | 7589908 | ||
| C0023601 | streptozocin | D013311 | 18883-66-4 | leydig cell tumor | MESH:D007984 | marker/mechanism | 6225653 | ||
FDA approved drug and dosage information(Total Drugs:6) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D007984 | prevacid | lansoprazole | 15MG | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription | AB | Yes | No |
| MESH:D007984 | prevacid | lansoprazole | 15MG/PACKET | FOR SUSPENSION, DELAYED RELEASE;ORAL | Discontinued | None | No | No |
| MESH:D007984 | prevacid | lansoprazole | 15MG | TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL | Prescription | None | Yes | No |
| MESH:D007984 | prevacid | lansoprazole | 15MG | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription | AB | Yes | No |
| MESH:D007984 | prevacid | lansoprazole | 15MG/PACKET | FOR SUSPENSION, DELAYED RELEASE;ORAL | Discontinued | None | No | No |
| MESH:D007984 | prevacid | lansoprazole | 15MG | TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL | Prescription | None | Yes | No |
FDA labeling changes(Total Drugs:6) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D007984 | 06/17/2004 | prevacid | lansoprazole | Short-term treatment of symptomatic GERD and erosive Esophagitis | Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients | Labeling | B | - | - | - | Tap | 07/15/2008 | FALSE' |
| MESH:D007984 | 06/17/2004 | prevacid | lansoprazole | Short-term treatment of symptomatic GERD and erosive Esophagitis | Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients | Labeling | B | - | - | - | Tap | 07/15/2008 | FALSE' |
| MESH:D007984 | 06/17/2004 | prevacid | lansoprazole | Short-term treatment of symptomatic GERD and erosive Esophagitis | Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients | Labeling | B | - | - | - | Tap | 07/15/2008 | FALSE' |
| MESH:D007984 | 10/28/2008 | prevacid | lansoprazole | Symptomatic GERD in infants | Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies | Labeling | - | - | B, P | - | Takeda | 07/15/2008 | FALSE' |
| MESH:D007984 | 10/28/2008 | prevacid | lansoprazole | Symptomatic GERD in infants | Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies | Labeling | - | - | B, P | - | Takeda | 07/15/2008 | FALSE' |
| MESH:D007984 | 10/28/2008 | prevacid | lansoprazole | Symptomatic GERD in infants | Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies | Labeling | - | - | B, P | - | Takeda | 07/15/2008 | FALSE' |